Posted by Michael Wonder on 25 Nov 2020
Rinvoq continues to be part of the high-cost protection with limited subsidy after reconsideration
25 November 2020 - TLV has reconsidered the subsidy for Rinvoq (upadacitinib monohydrate) and decided that the drug should continue to be included in the high-cost protection with limited subsidy.
The restriction means that the drug is only subsidised when treatment with TNF inhibitors has given insufficient effect or is not appropriate.
